Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ramon Cacabelos. (2020) Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 5:3, pages 181-234.
Read now
Read now
Articles from other publishers (5)
Dan Zhang, Wei Qin, Wenwen Du, Xiaoxing Wang, Wenqian Chen & Pengmei Li. (2022)
Effect of
ABCB1
gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non‐valvular atrial fibrillation
. Biopharmaceutics & Drug Disposition 43:4, pages 163-171.
Crossref
Crossref
Eric Rytkin, Irina V. Bure, Pavel O. Bochkov, Kristina A. Akmalova, Karin B. Mirzaev, Marina S. Cherniaeva, Olga D. Ostroumova, Valery V. Smirnov, Elena A. Grishina, Anna G. Saribekian, Igor N. Sychev & Dmitry A. Sychev. (2022) MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metabolism and Personalized Therapy 37:1, pages 41-46.
Crossref
Crossref
Belgin Susleyici, Cavlan Ciftci, Selen Yurdakul, Mehtap Cevik, Cansu Selcan Akdeniz, Ismail Polat Canbolat, Gokce Deliorman & Atila Karaalp. (2021) Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish
Patients: Preliminary Results, 2017. Current Pharmacogenomics and Personalized Medicine 18:2, pages 116-122.
Crossref
Crossref
D. A. Sychev & L. K. Moshetova. (2020) Problems of integrating medical science, image and practical health care: focus on personalized medicine. Pharmacogenetics and Pharmacogenomics:1, pages 3-10.
Crossref
Crossref
Wilbert Bor & Diana A. Gorog. (2020) Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. Journal of Clinical Medicine 9:7, pages 2020.
Crossref
Crossref